Persistent Allergic Rhinitis and the XPERT Study

Table 3 Changes of the RQLQ Domains at 4 Weeks From Baseline

	Placebo Change		Levocetirizine (5 mg) Change		Difference versus Placebo (95% CI)
Domain	N*	Adjusted Mean† (SEM)	N*	Adjusted Mean† (SEM)	Adjusted Mean	P
Activities	241	−1.36 (0.10)	248	−2.08 (0.10)	0.73 (0.47-0.99)	<0.001
Emotions	252	−0.81 (0.07)	257	−1.16 (0.07)	0.35 (0.17-0.54)	<0.001
Eye symptoms	252	−0.91 (0.09)	257	−1.40 (0.09)	0.48 (0.26-0.70)	<0.001
Non-hay fever symptoms	252	−0.83 (0.08)	257	−1.21 (0.08)	0.38 (0.18-0.57)	<0.001
Nasal symptoms	252	−1.10 (0.09)	257	−1.64 (0.09)	0.54 (0.31-0.77)	<0.001
Practical problems	252	−1.50 (0.10)	257	−2.06 (0.10)	0.56 (0.30-0.82)	<0.001
Sleep	252	−0.86 (0.09)	257	−1.35 (0.09)	0.50 (0.27-0.73)	<0.001

ISSN: 1939-4551